** Chimeric Therapeutics CHM.AX falls 7.7% to A$0.006, lowest since February 26
** Biotech firm says it intends to raise up to A$3.2 mln ($1.99 mln) at A$0.005, a discount of 28.6% to last close
** Adds funds will used for continued development of co's CDH17 Phase 1/2 clinical trial
** Stock down 14.3% YTD
($1 = A$1.6116)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。